- Home
- GNE vs ZNTL Comparison
GNE vs ZNTL Comparison
Compare GNE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNE | ZNTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 289.0M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNE | ZNTL |
|---|---|---|
| Price | $15.52 | $3.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $16.00 | $6.60 |
| AVG Volume (30 Days) | 62.8K | ★ 1.0M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.65 | 18.03 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $425,202,000.00 | N/A |
| Revenue This Year | $17.49 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $28.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.69 | $1.21 |
| 52 Week High | $16.28 | $6.95 |
Technical Indicators
Market Signals| Indicator | GNE | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 48.20 |
| Support Level | $13.45 | $3.46 |
| Resistance Level | $15.50 | $4.00 |
| Average True Range (ATR) | 0.47 | 0.19 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 78.71 | 90.62 |
Price Performance
Historical ComparisonAbout GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.